Table 4.
Patients, n (%) | RZB 150 mg N=224 |
PBO N=219 |
TEAEs reported in ≥2% of patients in either group | ||
Upper respiratory tract infection | 17 (7.6) | 12 (5.5) |
Hypertension | 10 (4.5) | 6 (2.7) |
Nasopharyngitis | 9 (4.0) | 8 (3.7) |
Arthralgia | 7 (3.1) | 7 (3.2) |
Nausea | 6 (2.7) | 4 (1.8) |
Psoriatic arthropathy | 6 (2.7) | 9 (4.1) |
Bronchitis | 5 (2.2) | 4 (1.8) |
Diarrhoea | 5 (2.2) | 5 (2.3) |
Headache | 5 (2.2) | 8 (3.7) |
PBO, placebo; RZB, risankizumab; TEAE, treatment-emergent adverse event.